These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
470 related articles for article (PubMed ID: 27461036)
1. Circulating Tumor DNA to Monitor Therapy for Aggressive B-Cell Lymphomas. Kwok M; Wu SP; Mo C; Summers T; Roschewski M Curr Treat Options Oncol; 2016 Sep; 17(9):47. PubMed ID: 27461036 [TBL] [Abstract][Full Text] [Related]
2. Monitoring clinical outcomes in aggressive B-cell lymphoma: From imaging studies to circulating tumor DNA. Melani C; Wilson WH; Roschewski M Best Pract Res Clin Haematol; 2018 Sep; 31(3):285-292. PubMed ID: 30213398 [TBL] [Abstract][Full Text] [Related]
3. Circulating Tumor DNA in Diffuse Large B-Cell Lymphoma: from Bench to Bedside? Cherng HJ; Herrera A Curr Treat Options Oncol; 2024 May; 25(5):659-678. PubMed ID: 38656685 [TBL] [Abstract][Full Text] [Related]
4. Circulating tumour DNA and CT monitoring in patients with untreated diffuse large B-cell lymphoma: a correlative biomarker study. Roschewski M; Dunleavy K; Pittaluga S; Moorhead M; Pepin F; Kong K; Shovlin M; Jaffe ES; Staudt LM; Lai C; Steinberg SM; Chen CC; Zheng J; Willis TD; Faham M; Wilson WH Lancet Oncol; 2015 May; 16(5):541-9. PubMed ID: 25842160 [TBL] [Abstract][Full Text] [Related]
5. Molecular Monitoring of Cell-Free Circulating Tumor DNA in Non-Hodgkin Lymphoma. Melani C; Roschewski M Oncology (Williston Park); 2016 Aug; 30(8):731-8, 744. PubMed ID: 27539624 [TBL] [Abstract][Full Text] [Related]
6. Next-generation sequencing-based detection of circulating tumour DNA After allogeneic stem cell transplantation for lymphoma. Herrera AF; Kim HT; Kong KA; Faham M; Sun H; Sohani AR; Alyea EP; Carlton VE; Chen YB; Cutler CS; Ho VT; Koreth J; Kotwaliwale C; Nikiforow S; Ritz J; Rodig SJ; Soiffer RJ; Antin JH; Armand P Br J Haematol; 2016 Dec; 175(5):841-850. PubMed ID: 27711974 [TBL] [Abstract][Full Text] [Related]
7. Tracking the evolution of untreated high-intermediate/high-risk diffuse large B-cell lymphoma by circulating tumour DNA. Zhang S; Zhang T; Liu H; Zhao J; Zhou H; Su X; Liu X; Li L; Qiu L; Qian Z; Zhou S; Gong W; Meng B; Ren X; He J; Wang X; Zhang H Br J Haematol; 2022 Feb; 196(3):617-628. PubMed ID: 34664256 [TBL] [Abstract][Full Text] [Related]
8. Clinical and prognostic significance of aberrant T-cell marker expression in 225 cases of de novo diffuse large B-cell lymphoma and 276 cases of other B-cell lymphomas. Tsuyama N; Ennishi D; Yokoyama M; Baba S; Asaka R; Mishima Y; Terui Y; Hatake K; Takeuchi K Oncotarget; 2017 May; 8(20):33487-33500. PubMed ID: 28380441 [TBL] [Abstract][Full Text] [Related]
9. Clinical implications of circulating tumor DNA in predicting the outcome of diffuse large B cell lymphoma patients receiving first-line therapy. Li M; Mi L; Wang C; Wang X; Zhu J; Qi F; Yu H; Ye Y; Wang D; Cao J; Hu D; Yang Q; Zhao D; Ma T; Song Y; Zhu J BMC Med; 2022 Oct; 20(1):369. PubMed ID: 36280874 [TBL] [Abstract][Full Text] [Related]
10. Minimal residual disease in non-Hodgkin lymphoma - current applications and future directions. Chase ML; Armand P Br J Haematol; 2018 Jan; 180(2):177-188. PubMed ID: 29076131 [TBL] [Abstract][Full Text] [Related]
11. Detection of Solid Tumor Molecular Residual Disease (MRD) Using Circulating Tumor DNA (ctDNA). Chin RI; Chen K; Usmani A; Chua C; Harris PK; Binkley MS; Azad TD; Dudley JC; Chaudhuri AA Mol Diagn Ther; 2019 Jun; 23(3):311-331. PubMed ID: 30941670 [TBL] [Abstract][Full Text] [Related]
12. Molecular Disease Monitoring in Patients With Relapsed/refractory B-Cell Lymphoma Receiving Anti-CD19 CAR T-Cell Therapy. Colton M; Purev E; Haverkos B; Bair S; Jasem J; Jacob A; Kamdar M Clin Lymphoma Myeloma Leuk; 2024 Nov; 24(11):778-782. PubMed ID: 39034202 [TBL] [Abstract][Full Text] [Related]
14. cfDNA-Based NGS IG Analysis in Lymphoma. Pott C; Kotrova M; Darzentas N; Brüggemann M; Khouja M; Methods Mol Biol; 2022; 2453():101-117. PubMed ID: 35622323 [TBL] [Abstract][Full Text] [Related]
15. VDJ-Seq: Deep Sequencing Analysis of Rearranged Immunoglobulin Heavy Chain Gene to Reveal Clonal Evolution Patterns of B Cell Lymphoma. Jiang Y; Nie K; Redmond D; Melnick AM; Tam W; Elemento O J Vis Exp; 2015 Dec; (106):e53215. PubMed ID: 26780364 [TBL] [Abstract][Full Text] [Related]
16. Distinct biological subtypes and patterns of genome evolution in lymphoma revealed by circulating tumor DNA. Scherer F; Kurtz DM; Newman AM; Stehr H; Craig AF; Esfahani MS; Lovejoy AF; Chabon JJ; Klass DM; Liu CL; Zhou L; Glover C; Visser BC; Poultsides GA; Advani RH; Maeda LS; Gupta NK; Levy R; Ohgami RS; Kunder CA; Diehn M; Alizadeh AA Sci Transl Med; 2016 Nov; 8(364):364ra155. PubMed ID: 27831904 [TBL] [Abstract][Full Text] [Related]
17. The combined expression of VPREB3 and ID3 represents a new helpful tool for the routine diagnosis of mature aggressive B-cell lymphomas. Soldini D; Georgis A; Montagna C; Schüffler PJ; Martin V; Curioni-Fontecedro A; Martinez A; Tinguely M Hematol Oncol; 2014 Sep; 32(3):120-5. PubMed ID: 24493312 [TBL] [Abstract][Full Text] [Related]
18. Noninvasive minimal residual disease assessment in relapsed/refractory large B-cell lymphoma using digital droplet PCR. Heger JM; d'Hargues Y; Kleinert F; Mattlener J; Weiss J; Franzen F; Becker C; Becker K; Gödel P; Schmiel M; Meinel J; Flümann R; Simon F; Reinhardt HC; Borchmann P; Borchmann S; Balke-Want H; Knittel G; von Tresckow B Eur J Haematol; 2024 Jun; 112(6):957-963. PubMed ID: 38369814 [TBL] [Abstract][Full Text] [Related]
19. Circulating tumour DNA in B-cell lymphomas: current state and future prospects. Lakhotia R; Roschewski M Br J Haematol; 2021 Jun; 193(5):867-881. PubMed ID: 33550600 [TBL] [Abstract][Full Text] [Related]
20. Clinical applications of circulating tumor DNA in indolent B-cell lymphomas. Lakhotia R; Roschewski M Semin Hematol; 2023 Jul; 60(3):164-172. PubMed ID: 37419716 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]